ERBB2 and breast carcinoma: In the BOLERO-2 study, the combination of everolimus and exemestane increased the ORR in postmenopausal women with hormone receptor-positive and HER2-negative advanced breast cancer to 12.6% compared with exemestane monotherapy (105–107), and extended the mPFS from 3.2 months to 7.8 months.